SLCO1B1 *15 allele is associated with methotrexate‐induced nausea in pediatric patients with inflammatory bowel disease
Abstract Low‐dose methotrexate (MTX) is an immunosuppressant used to treat inflammatory bowel disease (IBD). SLCO1B1 genetic variation has been associated with delayed MTX clearance and increased toxicity. The purpose of this study was to evaluate the association between SLCO1B1 genetic variation an...
Saved in:
Main Authors: | Rishi S. Mehta (Author), Zachary L. Taylor (Author), Lisa J. Martin (Author), Michael J. Rosen (Author), Laura B. Ramsey (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model
by: Zachary L. Taylor, et al.
Published: (2021) -
Effect of SLCO1B1 Polymorphisms on High‐Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma
by: Rachael R. Schulte, et al.
Published: (2021) -
Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia
by: Jonathan B. Wagner, et al.
Published: (2020) -
SLCO1B1 and CYP3A4 allelic variants associated with pharmacokinetic interactions and adverse reactions induced by simvastatin and atorvastatin used in Peru: Clinical implications
by: Angel T. Alvarado, et al.
Published: (2023) -
Alternative Splicing of the SLCO1B1 Gene: An Exploratory Analysis of Isoform Diversity in Pediatric Liver
by: Bianca D. vanGroen, et al.
Published: (2020)